Challenges in the Diagnosis and Individualized Treatment of Cervical Cancer

Medicina (Kaunas). 2023 May 11;59(5):925. doi: 10.3390/medicina59050925.

Abstract

Cervical cancer is still the fourth most common cancer in women throughout the world; an estimated 604,000 new cases were observed in 2020. Better knowledge of its pathogenesis, gained in recent years, has introduced new preventive and diagnostic approaches. Knowledge of its pathogenesis has made it possible to provide individualized surgical and drug treatment. In industrialized countries, cervical cancer has become a less frequent tumor entity due to the accessibility of the human papilloma virus vaccination, systematic preventive programs/early detection programs, health care infrastructure and the availability of effective therapy options. Nevertheless, globally, neither mortality nor morbidity has been significantly reduced over the past 10 years, and therapy approaches differ widely. The aim of this review is to address recent advances in the prevention, diagnostic investigation and treatment of cervical cancer globally, focusing on advances in Germany, with a view toward providing an updated overview for clinicians. The following aspects are addressed in detail: (a) the prevalence and causes of cervical cancer, (b) diagnostic tools using imaging techniques, cytology and pathology, (c) pathomechanisms and clinical symptoms of cervical cancer and (d) different treatment approaches (pharmacological, surgical and others) and their impact on outcomes.

Keywords: HPV; cervical cancer; checkpoint inhibitors; nerve-sparing radical hysterectomy; radiochemotherapy.

Publication types

  • Review

MeSH terms

  • Developed Countries
  • Early Detection of Cancer
  • Female
  • Humans
  • Immunization
  • Papillomavirus Infections* / prevention & control
  • Prevalence
  • Uterine Cervical Neoplasms* / prevention & control
  • Uterine Cervical Neoplasms* / therapy

Grants and funding

This research received no external funding.